Secukinumab is a recombinant, high-affinity, fully human immunoglobulin G1κ monoclonal antibody that selectively binds and neutralizes interleukin-17A, which stimulates keratinocytes to secrete chemokines and other proinflammatory mediators that recruit additional inflammatory cells, potentially acting as a master cytokine in psoriasis pathogenesis15. The gene discussed is IL17A; the disease is psoriasis.